US20060199831A1 - Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity - Google Patents
Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity Download PDFInfo
- Publication number
- US20060199831A1 US20060199831A1 US10/514,301 US51430105A US2006199831A1 US 20060199831 A1 US20060199831 A1 US 20060199831A1 US 51430105 A US51430105 A US 51430105A US 2006199831 A1 US2006199831 A1 US 2006199831A1
- Authority
- US
- United States
- Prior art keywords
- compositions
- hours
- temperature
- amino
- isoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to injectable pharmaceutical compositions containing 6,9-bis [(2-aminoethyl)amino]benzo [g]isoquinoline-5,10-dione dimaleate (from now on also referred to as “BBR 2778”) as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.
- BBR 2778 6,9-bis [(2-aminoethyl)amino]benzo [g]isoquinoline-5,10-dione dimaleate
- BBR 2778 is a novel anthracenedione derivative with anti-tumoral activity which acts as a DNA intercalating agent and topoisomerase II inhibitor. Pre-clinical studies demonstrate that its cardiotoxicity is lower than that of other known drugs belonging to the same class. BBR 2778 has proved more active than mitoxantrone against haematological tumours, especially ascitic L1210 leukaemia and YC-8 lymphoma, in a wide range of doses.
- BBR2778 in injectable liquid pharmaceutical compositions has proved problematic in terms of stability in solution using common solvents suitable for parenteral administration, especially intravenous administration.
- a lyophilised formulation to be reconstituted with a suitable solvent such as saline immediately before use has therefore been considered.
- a first aspect of the invention therefore provides injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo [g]isoquinoline-5,10-dione dimaleate (BBR 2778) as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride, to be reconstituted with a solvent suitable for reconstituting the lyophilisate and suitable for parenteral administration, which solvent is preferably contained in a separate ampoule.
- BBR 2778 6,9-bis[(2-aminoethyl)amino]benzo [g]isoquinoline-5,10-dione dimaleate
- a further aspect of the invention relates to a process for the preparation of said compositions.
- the weight ratio between the carrier and sodium chloride is critical, and is typically between 1:1 and 3:1.
- the weight ratio between BBR 2778 and the carrier is preferably between 1:2 and 1:6.
- the particularly preferred carrier is lactose.
- the unit dose of BBR 2778 will usually be between 25 and 200 mg, and preferably between 50 and 100 mg.
- the unit dose currently being tested in clinical trials is 50 mg.
- the preferred compositions according to the invention will contain 100 to 200 mg of sodium chloride and 100 to 300 mg of lactose.
- compositions of the invention can also contain other excipients commonly used for parenteral formulations, such as antioxidants, buffers, local anaesthetics, salts, amino acids and the like.
- the vials or ampoules of sterile lyophilised powder will then be reconstituted at the time of use with sterile solvents constituted by sterile pyrogen-free water or sterile saline, in volumes of approx. 5 ml to 20 ml, depending on the active ingredient content.
- compositions of the invention are prepared by a process which comprises lyophilisation of an aqueous solution of BBR 2778, lactose or dextran and sodium chloride by means of:
- compositions according to the invention are stable at room temperature for at least 24 months.
- the lyophilised product is not subject to deliquescence, and maintains its appearance unchanged over time.
- a farther advantage of the invention is the reduction in lyophilisation times and the consequent reduction in the cost of the process.
- a lyophilisation stopper is placed on the mouth of the vials.
- the pre-stoppered vials are then loaded directly onto lyophilisation shelves and frozen at ⁇ 45° C. ⁇ 5° C. for at least 3 hours.
- Primary drying is conducted by increasing the temperature of the shelves in the vacuum freeze-dryer from ⁇ 45° C. to ⁇ 30° C. ⁇ 3° C. in 3 hours, and maintaining the temperature at ⁇ 30° C. for 40 hours.
- Secondary drying is performed by increasing the temperature of the shelves from ⁇ 30° C. to +30° C. ⁇ 3° C. in 10 hours and then maintaining said temperature of +30° C. for a further 8 hours.
- the freeze-dryer is returned to atmospheric pressure with nitrogen filtered under sterile conditions, and the vials are stoppered by activating the stoppering device.
- the vials are unloaded in a sterile environment and crimped.
- the solution When reconstituted with 5 ml of water for injection, the solution has a pH of between 3.0 and 4.5.
- a lyophilisation stopper is placed on the mouth of the vials.
- the pre-stoppered vials are then loaded onto trays, which are placed on the shelves of the freeze-dryer.
- the vials are then frozen in the lyophilisation chamber at ⁇ 45° C. ⁇ 5° C. for at least 3 hours.
- Primary drying is conducted by increasing the temperature of the shelves in the vacuum freeze dryer from ⁇ 45° C. to 0° C ⁇ 2° C. in 6 hours and maintaining the temperature at 0° C. for 30 hours.
- the temperature of the product during primary drying is maintained at around ⁇ 30° C.
- Secondary drying is performed by increasing the temperature of the shelves from 0° C. to +30° C. ⁇ 2° C. in 3 hours and then maintaining said temperature of +30° C. for a further 8 hours.
- the freeze-dryer is returned to atmospheric pressure with nitrogen filtered under sterile conditions, and the vials are stoppered by activating the stoppering device.
- the vials are unloaded in a sterile environment and crimped.
- the solution When reconstituted with 5 ml of water for injection, the solution has a pH of between 3.0 and 4.5.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/964,861 US9211262B2 (en) | 2002-05-16 | 2010-12-10 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
US14/937,689 US20160256557A1 (en) | 2002-05-16 | 2015-11-10 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002MI001040A ITMI20021040A1 (it) | 2002-05-16 | 2002-05-16 | Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale |
ITMI2002A001040 | 2002-05-16 | ||
PCT/EP2003/004871 WO2003097101A1 (en) | 2002-05-16 | 2003-05-09 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/004871 A-371-Of-International WO2003097101A1 (en) | 2002-05-16 | 2003-05-09 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/964,861 Continuation US9211262B2 (en) | 2002-05-16 | 2010-12-10 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060199831A1 true US20060199831A1 (en) | 2006-09-07 |
Family
ID=11449903
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/514,301 Abandoned US20060199831A1 (en) | 2002-05-16 | 2003-05-09 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
US12/964,861 Active 2024-08-09 US9211262B2 (en) | 2002-05-16 | 2010-12-10 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
US14/937,689 Abandoned US20160256557A1 (en) | 2002-05-16 | 2015-11-10 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/964,861 Active 2024-08-09 US9211262B2 (en) | 2002-05-16 | 2010-12-10 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
US14/937,689 Abandoned US20160256557A1 (en) | 2002-05-16 | 2015-11-10 | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
Country Status (12)
Country | Link |
---|---|
US (3) | US20060199831A1 (it) |
EP (1) | EP1503797B1 (it) |
JP (1) | JP4624780B2 (it) |
AT (1) | ATE381944T1 (it) |
AU (1) | AU2003240613A1 (it) |
CA (1) | CA2486001C (it) |
DE (1) | DE60318310T2 (it) |
ES (1) | ES2298521T3 (it) |
FR (1) | FR12C0064I2 (it) |
IT (1) | ITMI20021040A1 (it) |
MX (1) | MXPA04011348A (it) |
WO (1) | WO2003097101A1 (it) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105769757A (zh) * | 2016-03-26 | 2016-07-20 | 夏建明 | 一种治疗非霍奇金淋巴瘤的注射液及其制备方法 |
CN108113967A (zh) * | 2016-03-26 | 2018-06-05 | 夏建明 | 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2106788A1 (en) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Liquid and freeze dried formulations |
CN105997896B (zh) * | 2016-05-28 | 2019-07-05 | 长沙秋点兵信息科技有限公司 | 治疗非霍奇金淋巴瘤的注射用冻干粉及其制备方法 |
CN106176630B (zh) * | 2016-08-03 | 2019-01-04 | 湖北丽益医药科技有限公司 | 一种注射用马来酸匹杉琼无菌粉末的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3590124A (en) * | 1967-06-27 | 1971-06-29 | Us Navy | Blood transfusion fluids having reduced turbulent friction properties |
US4822785A (en) * | 1986-07-10 | 1989-04-18 | Eisai Co., Ltd. | Cephalosporin injection |
US5587382A (en) * | 1994-03-28 | 1996-12-24 | Boehringer Mannheim Italia, Spa | 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity |
US6225325B1 (en) * | 1997-11-10 | 2001-05-01 | G.D. Searle & Company | Use of alkylated iminosugars to treat multidrug resistance |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ241868A (en) | 1991-03-08 | 1995-05-26 | Univ Vermont | 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof |
JP3501471B2 (ja) * | 1992-06-15 | 2004-03-02 | 旭化成ファーマ株式会社 | カルシトニン類の安定化組成物および安定化法 |
JPH08126685A (ja) * | 1994-01-26 | 1996-05-21 | Shionogi & Co Ltd | デキストラン類の凍結乾燥方法 |
GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
IT1315253B1 (it) * | 1999-10-22 | 2003-02-03 | Novuspharma Spa | Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato |
-
2002
- 2002-05-16 IT IT2002MI001040A patent/ITMI20021040A1/it unknown
-
2003
- 2003-05-09 DE DE60318310T patent/DE60318310T2/de not_active Expired - Lifetime
- 2003-05-09 WO PCT/EP2003/004871 patent/WO2003097101A1/en active IP Right Grant
- 2003-05-09 EP EP03729997A patent/EP1503797B1/en not_active Expired - Lifetime
- 2003-05-09 MX MXPA04011348A patent/MXPA04011348A/es active IP Right Grant
- 2003-05-09 CA CA2486001A patent/CA2486001C/en not_active Expired - Lifetime
- 2003-05-09 US US10/514,301 patent/US20060199831A1/en not_active Abandoned
- 2003-05-09 AU AU2003240613A patent/AU2003240613A1/en not_active Abandoned
- 2003-05-09 AT AT03729997T patent/ATE381944T1/de not_active IP Right Cessation
- 2003-05-09 ES ES03729997T patent/ES2298521T3/es not_active Expired - Lifetime
- 2003-05-09 JP JP2004505097A patent/JP4624780B2/ja not_active Expired - Lifetime
-
2010
- 2010-12-10 US US12/964,861 patent/US9211262B2/en active Active
-
2012
- 2012-10-25 FR FR12C0064C patent/FR12C0064I2/fr active Active
-
2015
- 2015-11-10 US US14/937,689 patent/US20160256557A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3590124A (en) * | 1967-06-27 | 1971-06-29 | Us Navy | Blood transfusion fluids having reduced turbulent friction properties |
US4822785A (en) * | 1986-07-10 | 1989-04-18 | Eisai Co., Ltd. | Cephalosporin injection |
US5587382A (en) * | 1994-03-28 | 1996-12-24 | Boehringer Mannheim Italia, Spa | 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity |
US6225325B1 (en) * | 1997-11-10 | 2001-05-01 | G.D. Searle & Company | Use of alkylated iminosugars to treat multidrug resistance |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105769757A (zh) * | 2016-03-26 | 2016-07-20 | 夏建明 | 一种治疗非霍奇金淋巴瘤的注射液及其制备方法 |
CN108113967A (zh) * | 2016-03-26 | 2018-06-05 | 夏建明 | 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法 |
CN108186560A (zh) * | 2016-03-26 | 2018-06-22 | 夏建明 | 一种治疗非霍奇金淋巴瘤的注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
ITMI20021040A0 (it) | 2002-05-16 |
FR12C0064I1 (it) | 2012-12-14 |
US20110144147A1 (en) | 2011-06-16 |
ITMI20021040A1 (it) | 2003-11-17 |
CA2486001A1 (en) | 2003-11-27 |
ATE381944T1 (de) | 2008-01-15 |
CA2486001C (en) | 2010-04-13 |
WO2003097101A1 (en) | 2003-11-27 |
JP2005530792A (ja) | 2005-10-13 |
EP1503797B1 (en) | 2007-12-26 |
DE60318310T2 (de) | 2008-12-11 |
ES2298521T3 (es) | 2008-05-16 |
FR12C0064I2 (fr) | 2013-08-16 |
AU2003240613A1 (en) | 2003-12-02 |
US20160256557A1 (en) | 2016-09-08 |
EP1503797A1 (en) | 2005-02-09 |
JP4624780B2 (ja) | 2011-02-02 |
US9211262B2 (en) | 2015-12-15 |
DE60318310D1 (de) | 2008-02-07 |
MXPA04011348A (es) | 2005-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11517609B2 (en) | Glycopeptide compositions | |
US20160256557A1 (en) | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity | |
EA013324B1 (ru) | Фармацевтические композиции бендамустина, предназначенные для лиофилизации | |
SK279869B6 (sk) | Farmaceutický lyofilizovaný prípravok na báze ifos | |
EP3218061B1 (en) | Carmustine pharmaceutical composition | |
CA3040018A1 (en) | Pharmaceutical parenteral formulation containing carglumic acid | |
EP3008064B1 (en) | Stable pemetrexed arginine salt and compositions comprising it | |
WO2022129264A1 (en) | Aqueous solution | |
WO2022129263A1 (en) | Aqueous solution | |
JP2019502720A (ja) | バンコマイシンの製剤 | |
WO2016005995A2 (en) | Glycol free stable liquid compositions of bendamustine | |
US5972912A (en) | Method for lyophilizing ifosfamide | |
WO2010025011A1 (en) | Formulations of canfosfamide and their preparation | |
US9765108B2 (en) | Formulation of 5-azacytidine | |
EP4070785A1 (en) | Lyophilized composition of copanlisib salt | |
WO2023214433A1 (en) | Stable parenteral compositions of parecoxib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELL THERAPEUTICS EUROPE S.R.I., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERNAREGGI, ALBERTO;LIVI, VALERIA;REEL/FRAME:016858/0560 Effective date: 20050615 |
|
AS | Assignment |
Owner name: CELL THERAPEUTICS, INC., WASHINGTON Free format text: MERGER;ASSIGNORS:CELL THERAPEUTICS EUROPE, SRL;CELL THERAPEUTICS, INC.;REEL/FRAME:021435/0506 Effective date: 20071108 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |